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Abstract: To investigate the antidepressant effect of high-dose milnacipran, we retrospectively 
compared three groups of inpatients with major depression; those who were given milnacipran 
100–150 mg/day (high-dose milnacipran group), those treated with milnacipran at maximum 
doses of 50–100 mg/day (standard-dose milnacipran group), and those treated with paroxetine 
at maximum doses of 40 mg/day (paroxetine group). The Hamilton Depression Rating Scale 
(HAM-D) scores of the three groups showed signiﬁ  cant decrease at discharge compared to the 
scores at admission, indicating improvement of depressive symptoms for each group. However, 
the mean HAM-D score on admission was signiﬁ  cantly lower for the standard-dose milnacipran 
group than the high-dose milnacipran and paroxetine groups. Additional intermediate assessment 
of the high-dose milnacipran group showed that the effect of milnacipran was dose-dependent 
with an additional improvement when patients were increase from 100 to 150 mg/day. These 
results suggest that patients suffering from moderate to severe depression with relative high 
HAM-D scores may beneﬁ  t from treatment with high-dose milnacipran.
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Introduction
Milnacipran is a dual action antidepressant (serotonin and norepinephrine reuptake 
inhibitor) which is commonly used in Japan and some European countries. The 
antidepressant was introduced into Japan ﬁ  ve years ago and it has been used as the 
ﬁ  rst-line treatment for depression and depressive state alongside selective serotonin 
reuptake inhibitors (SSRIs). In Japan, the optimal dose of milnacipran is generally 
considered to be between 50 and 100 mg/day, and some European studies have reported 
that no marked differences were observed in response rates between the dosage of 
100 mg/day and 200 mg/day (Serre et al 1987; Guelﬁ   et al 1998). On the other hand, 
Puozzo et al (1985, 1996) showed that the blood levels of the drug increased in a 
dose-dependent manner from 25 to 200 mg/day and that milnacipran inhibited the 
reuptake of noradrenaline and serotonin in a dose-dependent manner at doses from 
25 to 400 mg/day. In addition, Ansseau et al (1989) showed that the antidepressant 
effect of milnacipran was greater at 100 mg/day than 50 mg/day, suggesting a dose-
dependent treatment effect.
The purpose of the present study was to further evaluate, in a clinical setting, the rela-
tionship between the antidepressant effect of milnacipran and its dose. In Japan, when a 
dose of milnacipran up to 100 mg/day fails to produce a sufﬁ  cient antidepressant response, 
the patient is often switched to another antidepressant instead of receiving a higher dose of 
milnacipran. However, we have often encountered patients who have responded favourably 
to milnacipran at doses higher than 100 mg/day. Indeed, there have been several reports 
in Japan of the usefulness of treatment with milnacipran at doses exceeding 100 mg/day 
(Suzuki et al 2002; Morishita et al 2003; Kanemoto et al 2004). Von Frenckell et al (1990) 
showed that milnacipran given at a high dose of 200 mg/day was more effective than the Neuropsychiatric Disease and Treatment 2007:3(5) 700
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standard-dose treatments (50 mg/day or 100 mg/day), and that 
200 mg/day milnacipran was of comparable effectiveness to 
amitriptyline given at 150 mg/day.
The maximum doses of conventional tricyclic antidepres-
sants range from 150 to 300 mg/day, while the upper limit of 
milnacipran dose has been set at 100 mg/day. This difference 
in maximum dosage may explain the apparent insufﬁ  cient 
antidepressant effect of milnacipran which is sometimes 
found in some patients.
In the present study, we retrospectively selected inpatients 
diagnosed with a major depressive episode and classiﬁ  ed 
them into two groups according to the dose of milnacipran 
received: standard treatment (100 mg/day or less) and high-
dose treatment given at doses over 100 mg/day and up to 
150 mg/day. We compared these patients with those treated 
with paroxetine, which is currently the most frequently pre-
scribed antidepressant in Japan.
The present study was carried out in accordance with the 
principles of the Declaration of Helsinki.
Methods
The study was a retrospective case study of 84 consecutive 
depressive patients who were admitted to the psychiatry 
ward, Showa University Hospital during the period from 
April 1, 2004 to March 31, 2005. These 84 patients were 
diagnosed with major depressive episodes according to 
the Diagnostic and Statistical Manual of Mental Disorders, 
Fourth Edition (DSM-IV) by their psychiatrists. They were 
either antidepressant drug-naïve or off medication at least 
for one week on admission. Those who met the following 
criteria were included in the present study:
1.  Received antidepressant treatment with either milnacip-
ran or paroxetine as monotherapy.
2.  Aged between 20 and 70 years.
3.  Patients were classiﬁ  ed into standard-dose treatment group 
if they had received the milnacipran at maximum doses 
from 50 to 100 mg/day; into the high-dose treatment group 
if they had been given milnacipran with a maximum dose 
of greater than 100 mg/day and up to 150 mg/day. Patients 
were excluded from the study if they had a maximum dose 
of milnacipran below 50 mg/day or received milnacipran 
treatment at the maximum dose for less than two weeks.
4.  Patients given paroxetine were included if they had 
received the drug at a maximum dose of 40 mg/day for 
more than two weeks.
5.  All patients were required to have available assessment 
data (HAM-D rating) on admission and at the time of 
discharge.
Patients were excluded if:
1.  They met the diagnostic criteria of psychiatric diseases 
other than depression such as panic disorder, obsessive-
compulsive disorder, and schizophrenic mood disorder 
according to DSM-IV.
2.  They suffered serious heart, liver, or kidney diseases or 
suffered neurological diseases including cerebrovascular 
disorder and epilepsy.
A total of 49 subjects (16 males and 33 female) with a 
mean age of 57.1 ± 16.8 years were enrolled in the study 
(Table 1). Eighteen patients (6 males and 12 females; mean 
age 58.2 ± 15.1 years) were included in the high-dose 
milnacipran group. Their mean hospitalisation period was 
111.6 ± 68.4 days. Sixteen patients (2 males and 14 females, 
mean age 57.5 ± 19.5 years) were included in the standard-
dose milnacipran group. Their mean hospitalisation period 
was 65.8 ± 44.1 days. Fifteen patients (8 males and 7 females, 
mean age 55.5 ± 16.8 years) were included in the paroxetine 
group. Their mean hospitalisation period was 72.9 ± 56.8 
days. The three groups were not statistically different for 
mean age or sex. The hospitalisation period for the high-dose 
milnacipran group was signiﬁ  cantly longer than the other 
two groups (p  0.05). Across all study subjects, concomi-
tantly used drugs were as follows: anxiolytics in 22 patients 
(44.9%), and hypnotics in 33 patients (79.6%).
In order to retrospectively assess improvement of symp-
toms, the 21-item HAM-D scores obtained on admission and at 
the time of discharge were used. In the high-dose milnacipran 
group, the patients with HAM-D scores available during the 
period of treatment at doses from 50 to 100 mg/day were 
selected for the additional intermediate assessment, in addition 
to the assessments on admission (before receiving milnacipran) 
and at the time of discharge (milnacipran given at 150 mg/day 
for more than two weeks). HAM-D scores on admission, at the 
time of completion of the low-dose treatment, and during the 
high-dose treatment were available for 12 patients.
Stat View version 5.0 was used for the statistical analysis. 
Changes in HAM-D scores were analysed using two tailed 
t-test. All error values are given as the standard deviation.
Results
In the high-dose milnacipran group, the mean HAM-D score 
on admission and at the time of discharge were 26.9 ± 8.1 and 
10.4 ± 5.6, respectively (Table 1). For patients who received par-
oxetine (40 mg/day), the mean HAM-D score on admission and 
at the time of discharge were 25.9 ± 7.6 and 10.8 ± 7.8, respec-
tively. For these two groups, symptoms improved signiﬁ  cantly 
and to a similar degree, indicating no signiﬁ  cant inter-group Neuropsychiatric Disease and Treatment 2007:3(5) 701
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difference (Figure 1). In the standard-dose milnacipran group, 
the mean HAM-D score at the time of discharge also signiﬁ  cantly 
improved to 10.7 ± 5.4 compared to admission. However, the 
mean HAM-D score on admission was signiﬁ  cantly lower 
(p < 0.5) for the standard-dose milnacipran group (21.1 ± 4.6) than 
the high-dose milnacipran or paroxetine groups (Figure 1).
In 12 patients who started milnacipran at the standard-dose 
and subsequently increased to 150 mg/day, a dose-dependent 
two-step improvement of symptoms was observed (Figure 2).
Adverse effects occurred in one patient in the high-dose 
milnacipran group (nausea), and three patients in the parox-
etine group (two cases of nausea and one case of tremor).
Discussion
HAM-D scores improved signiﬁ  cantly during hospitalisation in 
both the standard-dose and the high-dose milnacipran groups. 
The improvement of depressive symptoms was comparable 
between the high-dose milnacipran group and the paroxetine 
40 mg/day group. Retrospective assessment revealed that patients 
with higher HAM-D scores on admission were more likely to be 
given milnacipran at a dose of 150 mg/day. These ﬁ  ndings sug-
gest that patients with mild depression and low HAM-D scores 
on admission could be sufﬁ  ciently treated with milnacipran at 
the standard-dose (50 mg/day to 100 mg/day), while patients 
suffering from moderate to severe symptoms demonstrated 
by higher HAM-D scores might need an increase in dosage of 
milnacipran up to 150 mg/day to improve their symptoms. This 
suggests that if a patient responds poorly to the standard-dose 
milnacipran treatment, it may be helpful to increase the dose up 
to 150 mg/day while assessing patient responses.
Table 1 Principal characteristics of the three patient groups
 Standard-dose  High-dose  Paroxetine
 milnacipran  milnacipran
n  16 18  15
Sex ratio  2/14  6/12  8/7
(male/female)
Age (years)  57.5 ± 19.5  58.2 ± 15.1  55.5 ± 16.8
(mean ± SD)
HAM-D 21.1  ± 4.6*  26.9 ± 8.1  25.9 ± 7.6
admission
(mean ± SD)
HAM-D 10.7  ± 5.4  10.4 ± 5.6  10.8 ± 7.8
discharge
(mean ± SD)
Length of  65.8 ± 44.1  111.6 ± 68.4*  72.9 ± 56.8
hospitalisation
(days)
(mean ± SD)
*0.05 compared to the other two groups.
Figure 1 Changes in HAM-D scores after milnacipran treatment at doses of up to 100 mg/day and 150 mg/day and paroxetine at a dose of 40 mg/day *** indicate a signiﬁ  -
cant difference (p  0.001) from admission.
milnacipran 150 mg/day
milnacipran ≤100 mg/day
paroxetine 40 mg/day
*** ***
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*** p < 0.001 compared to admission
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The present study has various limitations. In this 
retrospective study, there was no common scheme of dose 
escalation for milnacipran treatment. The timing of HAM-D 
assessment was not strictly controlled. In addition, only a 
small number of adverse effects were reported because none 
of the patients who had stopped treatment were included 
in the assessment. These “dropouts” should be included in 
the assessment in order to evaluate adverse effects directly 
caused by high doses of milnacipran. The limited number 
of patients together with possible effects of concomitant 
drugs in the present study are also weaknesses of this study. 
A prospective study designed to compare standard-doses 
of milnacipran and titration to higher doses in the Japanese 
context is clearly warranted.
Conclusion
The results of the present study suggest that patients suffering 
from moderate to severe depressive symptoms with relatively 
high HAM-D scores may beneﬁ  t from two-step increment 
of milnacipran up to 150 mg/day.
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